These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35808966)

  • 41. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
    Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
    Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
    Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
    Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzyme-Triggered Transcytosis of Dendrimer-Drug Conjugate for Deep Penetration into Pancreatic Tumors.
    Wang G; Zhou Z; Zhao Z; Li Q; Wu Y; Yan S; Shen Y; Huang P
    ACS Nano; 2020 Apr; 14(4):4890-4904. PubMed ID: 32286784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy.
    Mukai Y; Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2018 Jul; 25(7):1868-1879. PubMed ID: 29675761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy.
    Wang JQ; Wang LY; Li SJ; Tong T; Wang L; Huang CS; Xu QC; Huang XT; Li JH; Wu J; Zhao W; Yin XY
    Nanoscale; 2020 Aug; 12(29):15767-15774. PubMed ID: 32729861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.
    Shah VM; Sheppard BC; Sears RC; Alani AW
    Cancer Lett; 2020 Nov; 492():63-70. PubMed ID: 32822815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
    Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
    Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
    PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients.
    Ichikawa K; Mizuno S; Hayasaki A; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Usui M; Sakurai H; Isaji S
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30974894
    [No Abstract]   [Full Text] [Related]  

  • 57. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.
    Zhang Y; Frampton AE; Kyriakides C; Bong JJ; Habib N; Ahmad R; Jiao LR
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):1063-71. PubMed ID: 22392075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
    Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
    World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
    Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
    World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.